Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
156.50    -2.00 (-1.26%)
Bid:
156.00
Ask:
157.50
Spread: 1.50 (0.962%)
Market Cap: £1.35b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

UK SMALLCAP ROUNDUP: Antisoma To Return Cash If Programs Fail

Thu, 29th Jul 2010 12:30
Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps ANTISOMA PLC (ASM.LN), a biotechnology company, said it will return any cash it has left to shareholders if its two lead drug programs fail clinical trials. The firm posted a wider loss for the last fiscal year and said it expects to publish data from its two most advanced drug programs in the first half of 2011. AS1413 and AS1411 are both being tested as treatments for a type of blood cancer. At 1045 GMT, shares -0.01 pence, or 0.2%, at 5.5 pence. HORNBY PLC (HRN.LN), a U.K. toymaker, Thursday said fiscal year 2011 sales are set to be more heavily-weighted to its second half, as it has stepped up the distribution of its products to larger retailers who buy in stock in anticipation of the peak Christmas selling season. The firm, whose toys include Scalextric racing cars, Hornby model trains and Airfix, said like every year, its full-year result depends on consumer confidence and demand in the pre-Christmas period. At 1045 GMT, shares +12 pence, or 11%, at 122 pence. UNITED DRUG PLC (UDG.DB), an Irish drug wholesaler, Thursday said cuts to drug prices by the Irish government hurt revenue during the third quarter of its fiscal year. United Drug said revenue declined but it outperformed the market and gained market share. It said it expects pretax profit for the year to Sept. 30 to be broadly in line with the previous year. Pretax profit for the year to Sept. 30, 2009, was EUR39.1 million. At 1045 GMT, London-listed shares flat at 198 pence. RANK GROUP PLC (RNK.LN) said it is optimistic about its second half despite lingering consumer spending pressures, after it posted a surge in first-half pretax profit due to more customers being attracted to its casinos and bingo halls. The firm said comparable revenue across all its businesses rose in the first four weeks of the new half. At 1045 GMT, shares +13 pence, or 11.5%, at 122 pence. CONNAUGHT PLC (CNT.LN) Thursday said it has agreed terms on a GBP15 million short-term overdraft with its lenders and will continue negotiations with its lenders aimed at restructuring its financing. Connaught, which offers services such as compliance, social housing and environmental support services, warned Monday it will breach its banking covenants and its year-end net debt will be "significantly in excess" of the GBP120 million it forecast less than a month ago, saying it urgently needed cash. At 1045 GMT, shares +5 pence, or 15%, at 36 pence. COLLINS STEWART PLC (CLST.LN) is targeting a dozen fundraising deals in the second half, Chief Executive Mark Brown said, around double the amount of deals it carried out in the first half. "We do have a pipeline of deals for the second half, and it's looking better than the first half," he said. "It's now a question of whether we can execute it." At 1045 GMT, shares -2 pence, or 3%, at 73 pence. A.G. BARR PLC (BAG.LN), a soft drinks maker, said it expects its full-year result to top current management expectations, following a strong first half in which it expects to grow sales 13% on last year, although it expects tougher trading in its second half. At 1045 GMT, shares +11 pence, or 0.9%, at 1,197 pence. TRINITY MIRROR PLC (TNI.LN) posted a jump in first-half pretax profit as it benefited from a non-recurring GBP28.8 million gain and cost cuts and said it is optimistic about full-year prospects based on more cost-savings and stabilizing revenue. The publisher of titles such as the Daily Mirror and the People said it expects the rate of revenue decline to slow further during the second half, although it continues to expect month-on-month volatility. At 1045 GMT, shares +16 pence, or 20.8%, at 92 pence. ACAL PLC (ACL.LN), which sells components to manufacturers of electronics for aerospace, industrial and defense customers, said sales were up 20% and orders increased 29% during the first quarter of its fiscal year, as bumper sales at its electronics unit offset a weaker performance at its non-electronics business. At 1045 GMT, shares +13 pence, or 6.9%, at 195 pence. HUTCHISON CHINA MEDITECH LTD. (HCM.LN) reported a narrower net loss for the first six months of 2010, following strong sales of its heart pills in China and organic foods in Hong Kong. At 1045 GMT, shares -3 pence, or 1%, at 342 pence. PARAGON GROUP OF COS. PLC (PAG.LN), a buy-to-let lender, said it is still in talks with wholesale lenders with the aim of restarting lending, and that its third-quarter financial performance was strong. At 1045 GMT, shares +0.1 pence, or 0.1%, at 136.3 pence. DJ UK Smaller Cos +0.5% AIM +0.37% -By Hannah Benjamin, Rachael Gormley & Jason Douglas, Dow Jones Newswires; +44 (0) 20 7842 9298; uksmallcaps@dowjones.com (END) Dow Jones Newswires July 29, 2010 07:30 ET (11:30 GMT)

Related News

Paragon Banking to sell vehicle and fleet subsidiary SFS for £85.6m
7 hours ago

Paragon Banking to sell vehicle and fleet subsidiary SFS for £85.6m

(Sharecast News) - Paragon Banking Group said on Monday that it has agreed to sell subsidiary Specialist Fleet Services Limited (SFS) to NRG Fleet Ser...

Paragon to sell Specialist Fleet Services unit for GBP85.6 million
7 hours ago

Paragon to sell Specialist Fleet Services unit for GBP85.6 million

(Alliance News) - Paragon Banking Group PLC on Monday said it has agreed to sell its Specialist Fleet Services Ltd subsidiary to NRG Fleet Services Lt...

Hutchmed highlights data for sovleplenib in rare blood disorder
12 Jun 2026

Hutchmed highlights data for sovleplenib in rare blood disorder

(Alliance News) - Hutchmed China Ltd on Friday said phase III trial results for its investigational drug sovleplenib showed significant efficacy and a...

Hutchmed News

Hutchmed highlights data for sovleplenib in rare blood disorder
12 Jun 2026

Hutchmed highlights data for sovleplenib in rare blood disorder

(Alliance News) - Hutchmed China Ltd on Friday said phase III trial results for its investigational drug sovleplenib showed significant efficacy and a...

TRADING UPDATES: Tungsten secures loan; Ashtead trading in line
21 May 2026

TRADING UPDATES: Tungsten secures loan; Ashtead trading in line

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

EARNINGS AND TRADING: AltynGold reports annual revenue surge
29 Apr 2026

EARNINGS AND TRADING: AltynGold reports annual revenue surge

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately repor...

Hutchmed begins phase-three trials of lymphoma therapy in China
23 Mar 2026

Hutchmed begins phase-three trials of lymphoma therapy in China

(Alliance News) - Hutchmed China Ltd on Monday said it had begun phase-three clinical trials of its lymphoma treatment in China.

LONDON BRIEFING: GSK gains Japan nod; Anglo to delist shares in Zurich
23 Mar 2026

LONDON BRIEFING: GSK gains Japan nod; Anglo to delist shares in Zurich

(Alliance News) - GSK makes regulatory progress in Japan for a cancer therapy, Anglo American moves to delist from the Swiss exchange as part of its r...

Hutchmed shares slide as recalls cancer treatment Tazverik
9 Mar 2026

Hutchmed shares slide as recalls cancer treatment Tazverik

(Alliance News) - Hutchmed China Ltd on Monday saw its shares fall after reporting the withdrawal of a cancer medication which it licenses from Ipsen ...

Hutchmed China 2025 profit surges on divestment but revenue falls
5 Mar 2026

Hutchmed China 2025 profit surges on divestment but revenue falls

(Alliance News) - Hutchmed China Ltd on Thursday reported lower revenue for 2025, but reported sharply higher profit following a major divestment gain...